- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/40 - Oxygen atoms
Patent holdings for IPC class C07D 211/40
Total number of patents in this class: 115
10-year publication summary
|
10
|
5
|
8
|
8
|
7
|
5
|
6
|
8
|
10
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| FMC Corporation | 847 |
5 |
| Theravance Biopharma R&D IP, LLC | 460 |
5 |
| ChemoCentryx, Inc. | 387 |
4 |
| F. Hoffmann-La Roche AG | 7934 |
3 |
| AstraZeneca AB | 2928 |
3 |
| Amgen Inc. | 4071 |
3 |
| Bristol-myers Squibb Company | 4879 |
2 |
| Board of Regents, The University of Texas System | 5763 |
2 |
| ABAC Therapeutics S.L. | 7 |
2 |
| Athenex, Inc. | 26 |
2 |
| Neurocrine Biosciences, Inc. | 409 |
2 |
| Nippon Soda Co., Ltd. | 894 |
2 |
| Sirna Therapeutics, Inc. | 111 |
2 |
| Idorsia Pharmaceuticals Ltd. | 350 |
2 |
| Shanghai Meizer Pharmaceuticals Co., Ltd. | 14 |
2 |
| Vividion Therapeutics, Inc. | 34 |
2 |
| ReNAgade Therapeutics Management Inc. | 44 |
2 |
| Hong Kong King-friend Industrial Company Ltd. | 40 |
2 |
| Hoffmann-La Roche Inc. | 3404 |
1 |
| BASF SE | 20892 |
1 |
| Other owners | 66 |